Literature DB >> 12917251

Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides.

Joan Gavaldá1, Pedro López Onrubia, Mariá Teresa Martín Gómez, Xavier Gomis, José Luis Ramírez, Oscar Len, Dolors Rodríguez, Manuel Crespo, Isabel Ruíz, Albert Pahissa.   

Abstract

OBJECTIVE: This study tests the usefulness of ceftriaxone combined with ampicillin as an alternative to ampicillin plus gentamicin for the treatment of experimental endocarditis due to Enterococcus faecalis without high-level resistance to aminoglycosides. It also determines whether adding ceftriaxone to ampicillin and gentamicin increases the effectiveness against experimental enterococcal endocarditis resulting from E. faecalis.
METHODS: Animals with catheter-induced endocarditis were infected intravenously with 108 cfu of the EF91 strain of E. faecalis and were treated for 3 days with ampicillin 2 g every 4 h administered as 'human-like' (H-L) pharmacokinetics, plus gentamicin 1 mg/kg every 8 h H-L, or ceftriaxone 2 g every 12 h H-L alone or combined with gentamicin 6 mg/kg every 24 h administered subcutaneously.
RESULTS: The results of therapy for experimental endocarditis resulting from EF91 showed that the combination of ampicillin plus ceftriaxone was as effective as ampicillin plus gentamicin. The triple combination did not improve on the overall efficacies of the two-drug combinations.
CONCLUSIONS: Because of its lower nephrotoxicity, ampicillin plus ceftriaxone may be a useful alternative therapy for E. faecalis endocarditis in selected patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12917251     DOI: 10.1093/jac/dkg360

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  25 in total

Review 1.  Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.

Authors:  Sebastiano Leone; Silvana Noviello; Silvano Esposito
Journal:  Infection       Date:  2015-09-01       Impact factor: 3.553

Review 2.  Epidemiology and antibiotic treatment of infective endocarditis: an update.

Authors:  Bruno Hoen
Journal:  Heart       Date:  2006-11       Impact factor: 5.994

3.  Section 3: Prevention and Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

4.  The optimal aminoglycoside and its dosage for the treatment of severe Enterococcus faecalis infection. An experimental study in the rabbit endocarditis model.

Authors:  L Dubé; J Caillon; C Jacqueline; D Bugnon; G Potel; N Asseray
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-08       Impact factor: 3.267

Review 5.  Resistance in Vancomycin-Resistant Enterococci.

Authors:  William R Miller; Barbara E Murray; Louis B Rice; Cesar A Arias
Journal:  Infect Dis Clin North Am       Date:  2020-12       Impact factor: 5.982

Review 6.  Acute infective endocarditis.

Authors:  Jay R McDonald
Journal:  Infect Dis Clin North Am       Date:  2009-09       Impact factor: 5.982

7.  Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis.

Authors:  G Euba; J Lora-Tamayo; O Murillo; S Pedrero; J Cabo; R Verdaguer; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2009-08-10       Impact factor: 5.191

Review 8.  A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.

Authors:  Maya Beganovic; Megan K Luther; Louis B Rice; Cesar A Arias; Michael J Rybak; Kerry L LaPlante
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

Review 9.  The Enterococcus: a Model of Adaptability to Its Environment.

Authors:  Mónica García-Solache; Louis B Rice
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

10.  New perspectives of infections in cardiovascular disease.

Authors:  Ignatius W Fong
Journal:  Curr Cardiol Rev       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.